FGFR3 and urothelial carcinoma: Evidence from existing studies with other FGFR-driven cancers, such as urothelial carcinoma and cholangiocarcinoma, demonstrates the efficacy of pemigatinib in tumors that are refractory to conventional chemotherapeutic agents, especially FGFR3 alteration.